ABCC4

ATP-binding cassette sub-family C member 4 · O15439 · ABCC4 on Sugi Atlas →

161,957 patent compounds predicted against ABCC4, 130,820 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Rifamycin (SCHEMBL2320)	0.70	4/20
Glimepiride (SCHEMBL16084)	1.00	3/20
Glimepiride (SCHEMBL16086)	1.00	3/20
Sildenafil (SCHEMBL1895)	1.00	2/20
Atorvastatin (SCHEMBL3832)	1.00	2/20
Nifedipine (SCHEMBL3968)	1.00	2/20
Everolimus (SCHEMBL4378)	1.00	2/20
Saquinavir (SCHEMBL6881)	1.00	2/20
Misoprostol (SCHEMBL7787)	1.00	2/20
Misoprostol (SCHEMBL7788)	1.00	2/20
Rubitecan (SCHEMBL8640)	1.00	2/20
Valrubicin (SCHEMBL12824)	1.00	2/20
Valrubicin (SCHEMBL12825)	1.00	2/20
Atorvastatin (SCHEMBL3831)	0.87	2/20
SCHEMBL1141	0.86	2/20
SCHEMBL1449	0.86	2/20
Cefotaxime (SCHEMBL15410)	0.86	2/20
Cefotaxime (SCHEMBL15411)	0.86	2/20
SCHEMBL1267	0.85	2/20
SCHEMBL1251	0.85	2/20

Clinical trials — most relevant to ABCC4 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Digoxin Dosing in Heart Failure: A Simplified Nomogram Versus Standard Care	PHASE4	COMPLETED
Study of Neoadjuvant Docetaxel and Cyclophosphamide in Locally Advanced or Node Positive Primary Breast Cancer With Companion Pharmacokinetic and Pharmacogenomic Analyses	PHASE2	COMPLETED
Everolimus (RAD001) for Children With Chemotherapy-Refractory Progressive or Recurrent Low-Grade Gliomas	PHASE2	COMPLETED
A Phase 2 Trial of SCO-101 in Combination With FOLFIRI for Patients With Metastatic Colorectal Cancer (mCRC) With Acquired Resistance to FOLFIRI	PHASE1/PHASE2	UNKNOWN
Therapy for Children With Neuroblastoma	PHASE2	COMPLETED
Influence of Ethnicity and ABCB1 Gene Polymorphism on the Pharmacokinetics of Azithromycin in Healthy Bangladeshi Volunteers	PHASE1	UNKNOWN
Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery	PHASE1	COMPLETED
Icotinib Hydrochloride in Treating Patients With Advanced Cancers	PHASE1	WITHDRAWN
Indenoisoquinoline LMP744 in Adults With Relapsed Solid Tumors and Lymphomas	PHASE1	COMPLETED
Cilengitide in Treating Children With Refractory Primary Brain Tumors	PHASE1	COMPLETED
Effect of, OAT3, on the Renal Secretion of Cefotaxime	PHASE1	COMPLETED
Multidrug Resistance Genes in Patients With Acute Myeloid Leukemia	nan	ACTIVE_NOT_RECRUITING
the Effect of ABCC2 Genetic Polymorphism on Neurotoxicity in Gastrointestinal Cancer Patients Receiving Oxaliplatin	nan	UNKNOWN
Coproporphyrine Isomers and Methotrexate Elimination	nan	COMPLETED
Genetic Analysis of Patients With Pseudoxanthoma Elasticum	nan	COMPLETED
Placental Transfer of Tenofovir	nan	COMPLETED
Study of ABCB1,SLC22A16 Drug Transporter Genes and Doxorubicin and Cyclophosphamide Toxicity in Brest Cancer Patient	nan	UNKNOWN
Effect of Metformin on ABCB1 and AMPK Expression in Adolescents With Newly Diagnosed Acute Lymphoblastic Leukemia	nan	UNKNOWN
Impact of Genetics on Metformin Pharmacokinetics	nan	COMPLETED
Pharmacogenetics Study in Taiwan's Ethnic Groups	nan	COMPLETED
Metformin Reduce the Relapse Rate on Patients With B-cell Precursor (Ph+ Negative) Acute Lymphoblastic Leukemia	nan	COMPLETED
Evaluation of Pharmacogenetic Factors Affecting Fentanyl Requirements for Postoperative Pain Control	nan	COMPLETED
Role of Sorcin and Annexin A3 in Breast Cancer Patients	nan	UNKNOWN
ABCB4 Gene Mutations in Intrahepatic Cholestasis of Pregnancy and Controls	nan	COMPLETED
Pharmacogenomics of New Antiretrovirals	nan	COMPLETED
Collection of Tissue Samples for Study of Multidrug Resistance	nan	COMPLETED
Role of the ATP7A Transporter in Ovarian Cancer	nan	COMPLETED
Bile Acids Metabolism and Genetic Mutation Profile in the Intrahepatic Cholestasis of Pregnacy in Indian Population	nan	RECRUITING
An Observational Study in Children and Adults With Stargardt Disease	nan	ACTIVE_NOT_RECRUITING
Studying DNA in Tissue Samples From Caucasian and African-American Cancer Patients Who Received Docetaxel on Clinical Trial CLB-9871	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a ABCC4 binder may also engage these)

Protein	Name	Similarity
F1M3J4	—	1.000	F1M3J4 →
A0AAA9T569	—	1.000	A0AAA9T569 →
E9Q236	—	1.000	E9Q236 →
Q7FB56	—	0.991	Q7FB56 →
P21449	—	0.989	P21449 →
O35379	—	0.987	O35379 →
Q9QY30	—	0.987	Q9QY30 →
Q9C8G9	—	0.986	Q9C8G9 →
Q8HXQ5	—	0.986	Q8HXQ5 →
B5X0E4	—	0.986	B5X0E4 →
B2RX12	—	0.986	B2RX12 →
B8K1W2	—	0.986	B8K1W2 →
P06795	—	0.985	P06795 →
ABCC1	Multidrug resistance-associated protein 1	0.984	landscape →
Q5F364	—	0.984	Q5F364 →
Q6UR05	—	0.984	Q6UR05 →
P23174	—	0.984	P23174 →
Q864R9	—	0.984	Q864R9 →
P21440	—	0.982	P21440 →
Q08201	—	0.982	Q08201 →
Q9SKX0	—	0.982	Q9SKX0 →
Q8CG09	—	0.982	Q8CG09 →
Q9N0V3	—	0.982	Q9N0V3 →
P91660	—	0.982	P91660 →
Q9C8H0	—	0.981	Q9C8H0 →
Q42093	—	0.981	Q42093 →
ABCB1	ATP-dependent translocase ABCB1	0.981	landscape →
P43245	—	0.981	P43245 →
Q9JJ59	—	0.981	Q9JJ59 →
Q2M3G0	—	0.980	Q2M3G0 →